Cyprumed CEO Florian Föger (L) and COO Martin Werle (Credit: Company website)
Merck explores potential of oral peptides in deal with Austrian biotech
Merck is looking for ways to make its drugs easier to administer.
The large pharma is licensing a drug delivery platform from Austrian biotech Cyprumed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
